The incidence of clozapine-associated myocarditis is approximately 3%, rather than the usual estimate of under 1%, according to authors of a review published in Acta Psychiatrica Scandinavica.
1
Investigators from Monash University, Melbourne, Australia, searched the Medline database up to September 2014 for published cases of cases of clozapine-induced myocarditis and identified approximately 250 cases.
Possible missed cases, and reasons for possible undiagnosed myocarditis, were also assessed. Although fever was reported in patients initiating clozapine treatment, few patients with fever were investigated for myocarditis. However, the mean time to onset of fever (14 days) was consistent with a prodrome of undiagnosed myocarditis. Some cases of sudden death and respiratory disorders in patients receiving clozapine may have been due to undiagnosed myocarditis.
The diagnosis of myocarditis is difficult due to nonspecific signs and symptoms, and is dependent on appropriate investigations at the time of myocardial involvement or on biopsies of the myocardium in fatal cases, noted the authors. "Implementation of monitoring procedures will increase case ascertainment and result in more patients benefiting from this valuable medication," they said.
We believe that incidences of clozapine-induced myocarditis (1.1% and 5.0%) in two Australian studies in a total of under 300 patients titrated on clozapine should not be extrapolated to the thousands of patients titrated globally, said J. de Leon and colleagues in a Commentary published in Acta Psychiatrica Scandinavica. 2 "We suggest that instead of raising unfounded clinical concerns for non-Australians, Australian prescribers should consider adopting slower titrating schedules," they commented.
"I would argue that the relevant clinical question is not what the 'true' incidence of clozapine-induced myocarditis is," said O. Freudenreich in another Commentary published in Acta Psychiatrica Scandinavica, 3 "Instead, the message should be that, just like agranulocytosis, myocarditis can be detected early and it can be managed without many additional resources". He said that the risk of clozapine-induced myocarditis can be mitigated by measures such as routine monitoring of inflammatory markers and vital signs, assessing ECG changes and cardiac enzymes if clinical concerns arise, watching for increased eosinophil levels indicative of subclinical myocarditis, therapeutic drug level monitoring, and using a slow titration.
